Tin tức & Cập nhật

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.

Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.

Patients with inflammatory bowel disease (IBD) who undergo foecal microbiota transplantation (FMT) are less likely to develop recurrent Clostridioides difficile infection (CDI), a study has shown.